SQLite Web: event

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-21T19:57:20.275338+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:92990561870b1f0e","evidence_event_ids":["evt_208973333274"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/kopp-family-office-trims-35-million-worth-viridian-therapeutics-stake-what-investors","as_of":"2026-04-21T19:57:20.275338+00:00","canonical_url":"https://www.fool.com/coverage/filings/2026/04/21/kopp-family-office-trims-usd3-5-million-worth-of-viridian-therapeutics-stake-what-investors-should-know/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/kopp-family-office-trims-35-million-worth-viridian-therapeutics-stake-what-investors","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_8f002a0862bd7147","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/coverage/filings/2026/04/21/kopp-family-office-trims-usd3-5-million-worth-of-viridian-therapeutics-stake-what-investors-should-know/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-21T23:22:33.586080+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsKopp sold 117,878 shares of Viridian Therapeutics; the estimated transaction value was $3.5 million based on quarterly average pricing.","fetched_title":"Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know | Nasdaq","final_url":"https://www.nasdaq.com/articles/kopp-family-office-trims-35-million-worth-viridian-therapeutics-stake-what-investors","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/kopp-family-office-trims-35-million-worth-viridian-therapeutics-stake-what-investors","source_event_id":"evt_208973333274","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"301b9f43030e2d76","kind":"unusual_volume","published_at":"2026-04-21T19:46:26+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 20, 2026","Q1 2026","March 30, 2026","April 7, 2026","April 21, 2026","June 30, 2026","mid-March (year referenced in article)"],"entities":[{"asset_class":"equity_investor","name":"Kopp Family Office, LLC","relevance":"high","symbol":"","type":"fund_or_investor"},{"asset_class":"equity","name":"Viridian Therapeutics, Inc.","relevance":"high","symbol":"VRDN","type":"company"},{"asset_class":"equity","name":"Amgen","relevance":"medium","symbol":"AMGN","type":"company"}],"event_type":"other","information_gaps":["The signal type is 'discovery_unusual_volume_delta', but the provided article text does not include any volume ratio vs average, baseline volume, or confirmation that unusual trading volume occurred.","No explicit statement is provided that the sale was caused by unusual volume; the article discusses performance/competitive catalysts instead.","The article does not quantify the magnitude of the volume delta or whether it was confirmed by news beyond the described clinical/competitive events.","catalyst_hypothesis_most_likely_from_article:portfolio_discipline_amid_underperformance_and_recent_clinical_competitive_setbacks"],"key_facts":["SEC filing dated April 20, 2026 states Kopp Family Office reduced its Viridian Therapeutics stake by 117,878 shares during Q1 2026.","The transaction value is estimated at $3.5 million using the stock\u2019s average closing price for the quarter.","After the sale, Kopp still held 55,295 shares at quarter-end, valued at about $1.1 million (per the most recent 13F).","The Viridian position declined from 3.4% of Kopp\u2019s AUM in the prior quarter to 0.7% after the sale (13F reportable AUM).","The article notes the stock was priced at $14.29 as of April 21, 2026 and was up ~9% over the past year, while underperforming the S&P 500 by ~28 percentage points over the same period.","The article attributes recent market pressure to Phase 3 REVEAL-1 top-line data for elegrobart reported March 30, 2026 and to Phase 3 results reported by Amgen on April 7, 2026 for a subcutaneous version of Tepezza.","The article states Viridian\u2019s lead BLA program (veligrotug) has an FDA Priority Review with a PDUFA target date of June 30, 2026."],"numeric_claims":[{"label":"shares sold","value":"117,878"},{"label":"estimated transaction value","value":"$3.5 million"},{"label":"post-trade shares held","value":"55,295"},{"label":"post-trade value (as stated)","value":"$1.1 million"},{"label":"position as % of AUM before","value":"3.4%"},{"label":"position as % of AUM after","value":"0.7%"},{"label":"PDUFA target date","value":"June 30, 2026"},{"label":"stock price as of April 21, 2026","value":"$14.29"},{"label":"stock up over past year","value":"~9%"},{"label":"underperformance vs S&P 500","value":"~28 percentage points"}],"primary_claim":"Kopp Family Office, LLC trimmed its Viridian Therapeutics stake by 117,878 shares in Q1 2026 for an estimated ~$3.5 million, leaving 55,295 shares valued at ~$1.1 million (as of the most recent 13F).","relevance_score":0.62,"sentiment":"mixed","source_quality":"high","summary":"Kopp Family Office reduced its Viridian Therapeutics (NASDAQ:VRDN) stake by 117,878 shares (estimated ~$3.5M) in Q1 2026, cutting the position from 3.4% to 0.7% of its 13F reportable AUM. The article frames the trim as portfolio discipline amid VRDN\u2019s sharp underperformance and recent negative competitive/clinical readouts.","topics":["13F filing","insider/holder activity","portfolio trimming","clinical-stage biotech","VRDN competitive landscape","FDA catalyst timing"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsKopp sold 117,878 shares of Viridian Therapeutics; the estimated transaction value was $3.5 million based on quarterly average pricing.","tickers":[],"title":"Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know","url":"https://www.fool.com/coverage/filings/2026/04/21/kopp-family-office-trims-usd3-5-million-worth-of-viridian-therapeutics-stake-what-investors-should-know/"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — events

Update row 475742 in events